Applied DNA to Highlight Linea IVT Platform at mRNA Therapeutics Summit

Applied DNA Sciences, Inc. (NASDAQ: APDN), a leader in PCR-based DNA technologies, will present a poster at the 4th Annual mRNA-based Therapeutics Summit in Boston from July 29-31, 2024. The company's Linea™ IVT platform, designed to reduce double-stranded RNA (dsRNA) contamination, will be showcased as a high-yield solution for mRNA production.

The poster, titled "Reduction of dsRNA Contamination in High-Yield mRNA Production," will be presented by a team of authors including Yuhua Sun and Huan Dong. The presentation is scheduled for 3:45-4:30 p.m. on July 30, 2024.

Clay Shorrock, executive director of business development at LineaRx, highlighted that the Linea IVT platform addresses industry-wide concerns about dsRNA contamination, which can increase production costs and slow down mRNA synthesis. The platform combines enzymatically produced DNA templates with next-generation RNA polymerase to enhance mRNA manufacturing efficiency.